Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.795 USD | -0.72% | -2.83% | +14.29% |
May. 14 | Transcript : Absci Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Earnings Flash (ABSI) ABSCI CORPORATION Posts Q1 Revenue $898,000, vs. Street Est of $2.1M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.29% | 546M | C- | ||
+28.65% | 49.18B | B- | ||
+0.81% | 42.11B | B | ||
+50.47% | 40.37B | A | ||
-5.26% | 28.85B | C | ||
+13.38% | 26.09B | B- | ||
-22.40% | 18.71B | B | ||
+8.02% | 13.26B | B+ | ||
+31.92% | 12.32B | C+ | ||
-0.31% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABSI Stock
- Ratings Absci Corporation